Stock Price Quote

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1129.80-50.25 (-4.26 %)
PREV CLOSE ( ) 1180.05
OPEN PRICE ( ) 1194.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 15796
TODAY'S LOW / HIGH ( )1122.65 1196.55
52 WK LOW / HIGH ( )959.05 1592.55
NSE1131.35-48.6 (-4.12 %)
PREV CLOSE( ) 1179.95
OPEN PRICE ( ) 1190.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1131.35 (171)
VOLUME 1239852
TODAY'S LOW / HIGH( ) 1123.00 1199.00
52 WK LOW / HIGH ( )958.5 1592
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 26-12 1986
Management Info
M Ramasubramanian - Chairman K Nithyananda Reddy - Managing Director
Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone 040-23736370 / 23747340

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

14Feb Aurobindo Pharma’s arm gets marketing
Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologic..
07Feb Aurobindo Pharma reports 10% fall in Q
Aurobindo Pharma has reported results for third quarter ended December 3..
07Feb Aurobindo Pharma informs about integra
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated..
29Jan Aurobindo Pharma informs about new ord
Aurobindo Pharma has informed that the Company has received two orders f..
28Jan Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclos..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit4720.5000000000119541.4
Gross Profit 6329.40000000001 24029.2
Operating Profit 7674.1000000000128401
Net Sales 29166.3106456.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31796.37
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

NON-INSTITUTION 6.69%
PROMOTERS 51.82%
FI/BANKS/INSURANCE 5.12%
MUTUAL FUNDS/UTI 17.81%
GOVERNMENT 0%
FII 0%

About Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. was incorporated in the year 1986. Its today's share price is 1129.8. Its current market capitalisation stands at Rs 65618.97 Cr. In the latest quarter, company has reported Gross Sales of Rs. 106632.3 Cr and Total Income of Rs.112617 Cr. The company's management includes B Adi Reddy, Deepali Pant Joshi, Santanu Mukherjee, Girish Vanvari, P Sarath Chandra Reddy, Satakarni Makkapati, M Ramasubramanian, M Madan Mohan Reddy, PV Ramprasad Reddy, K Nithyananda Reddy.

It is listed on the BSE with a BSE Code of 524804 , NSE with an NSE Symbol of AUROPHARMA and ISIN of INE406A01037. It's Registered office is at Plot No. 2,Maitrivihar ,AmeerpetHyderabad-500038, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Associates LLP, Deloitte Haskins & Sells, K Nagaraju & Associates, SR Batliboi & Associates, SR Batliboi & Associates LLP, SR Batliboi & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.